Alvogen inks distribution agreement with Theramex

Privately-held US firm Alvogen and UK-based Theramex have entered into a binding agreement for an exclusive partnership and distribution deal for the commercialization of certain women’s health products in Russia, Central and Eastern Europe (CEE) as well as countries within the Commonwealth of Independent States (CIS).

The long-term partnership arrangement includes the rights to commercialize the Theramex portfolio of women’s health products such as Alpha D3 and Actonel (risedronate)for bone health as well as certain oral contraceptive products and future Theramex pipeline products.

Countries within the distribution agreement are: Russia, Kazakhstan, Ukraine, Estonia, Latvia, Lithuania, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Macedonia, Serbia and Slovenia. Whilst terms of the deal are not being disclosed, Alvogen will assume responsibility for sales, promotion and marketing of the products within the deal.  The portfolio generated $13.5 million in net revenues in 2017, with significant growth potential from future pipeline products.